netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Rituximab found 25 matches

Formulary items 9 matches
   
Open monograph to display formulary status BNF Category
  Rituximab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Rituximab Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Cytotoxic Drug Bendamustine Malignant disease and immunosuppression - Alkylating drugs - 08.01.01
  Cytotoxic Drug Idelalisib Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Lenalidomide Malignant disease and immunosuppression - Lenalidomide, pomalidomide, and thalidomide - 08.02.04
  Obinutuzumab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Cytotoxic Drug Pixantrone Malignant disease and immunosuppression - Anthracyclines and other cytotoxic antibiotics - 08.01.02
  Polatuzumab vedotin  (Polivy®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Venetoclax  (Venclyxto®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Dec 2013): Rituximab: screen for hepatitis B virus before treatment. (08.02.03)
link in drug section MHRA Drug Safety Update (Dec 2013): Rituximab: screen for hepatitis B virus before treatment. (10.01.03)
link in drug section MHRA Drug Safety Update (Dec 2014): Rituximab: progressive multifocal leukoencephalopathy in a patient (10.01.03)
link in drug section MHRA Drug Safety Update (Dec 2014): Rituximab: progressive multifocal leukoencephalopathy in a patient (08.02.03)
link in drug section NHSE Clinical Commissioning Policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)  (08.02.03)
link in drug section NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non- Hodgkin’s lymphoma (08.02.03)
link in drug section NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (08.02.03)
link in drug section NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (08.02.03)
link in drug section NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma (08.02.03)
link in drug section NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (08.02.03)
link in drug section NICE TA27: Lenalidomide with rituximab for previously treated follicular lymphoma (08.02.04)
link in drug section NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (08.01.05)
link in drug section NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (08.02.03)
link in drug section NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (08.01.05)
link in drug section NTAG - Rituximab for ITP in adults and children (08.02.03)
link in drug section NTAG - Treatment Appraisal Decision Summary - Rituximab Biosimilars (10.01.03)


 
netFormulary